Galectin's Belapectin Trial Shows Mixed Efficacy; $10M Credit Extends Runway to 2027
GALT has more than doubled off its 52-week low of $1.12.
Summary
Galectin Therapeutics reported its 2025 financial results and provided a business update, detailing mixed outcomes from its NAVIGATE Phase 2b/3 trial for belapectin in MASH cirrhosis. While the primary endpoint in the intent-to-treat population did not achieve statistical significance, the company highlighted a 49.3% reduction in varices in the per-protocol population (nominal p=0.04) and a 68.1% reduction in the U.S. per-protocol population (p=0.02). This update follows the company's 10-K filing earlier today, which broadly mentioned mixed clinical trial results and liquidity concerns. Crucially, the company secured a new $10 million line of credit from its Chairman, extending its cash runway through April 2027. The mixed trial results present a complex outlook for belapectin, with the primary endpoint miss being a significant challenge, but the positive subgroup data and new financing provide a clearer path for continued development. Investors will be watching for the upcoming FDA meeting in Q2 2026 to determine the optimal regulatory strategy and potential partnership discussions.
At the time of this announcement, GALT was trading at $2.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $165.7M. The 52-week trading range was $1.12 to $7.13. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.